Glomerulonephritis (Glomerulonephritis) is a rare and ultra-rare disease that can lead to kidney failure. The only way to diagnose the disease is a biopsy. Researchers want to prevent complications of the procedure in order to be able to diagnose kidney diseases earlier.

Glomerulonephritis (Glomerulonephritis) is associated with high comorbidity and mortality. In most cases, the only method of diagnosis is a kidney biopsy. - Despite the fact that it is a relatively safe examination, even a third of procedures are complicated by minor complications, most often of a hemorrhagic nature - explains Dr. hab. n. med. Alicja Rydzewska-Rosołowska from the Medical University of Bialystok, principal investigator in the "STOP BLEED" project. - These diseases are often diagnosed too late, which may be related to the fear (of both patients and doctors) of potential side effects of biopsy – he adds.

Desmopressin is successfully used in patients qualified for surgery who are at high risk of bleeding and seems to be an effective drug that can reduce the risk of bleeding after kidney biopsy. Scientists from the Medical University of Bialystok have designed a multi-centre clinical trial to assess the effectiveness of desmopressin in preventing bleeding complications after kidney biopsy. The study is funded by the Medical Research Agency.

- Adults qualified by a nephrologist for a kidney biopsy will be divided into two equal groups - one will receive a drug before the procedure, the other a placebo. The occurrence of minor and major bleeding complications within 24 hours after the procedure will be assessed, as well as the safety of the drug - explains Dr. hab. n. med. Alicja Rydzewska-Rosłowska from MUB.

The obtained results will make it possible to answer whether the use of desmopressin before kidney biopsy increases the safety of the procedure, especially in the population of people with rare kidney diseases.

Source: ABM